Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis

Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.Methods and results This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with rec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European Heart Journal 2020-06, Vol.41 (24), p.2248-2258
Hauptverfasser: Sinnaeve, P.R., Schwartz, G.G., Wojdyla, D.M., Alings, M., Bhatt, D.L., Bittner, V.A., Chiang, C.E., Flores, R.M.C., Diaz, R., Dorobantu, M., Goodman, S.G., Jukema, J.W., Kim, Y.U., Pordy, R., Roe, M.T., Sy, R.G., Szarek, M., White, H.D., Zeiher, A.M., Steg, P.G.
Format: Artikel
Sprache:eng
Schlagworte:
Acute coronary syndrome
Age
Alirocumab
Low-density lipoprotein cholesterol
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular risk irrespective of age, but the evidence is less strong for older patients.Methods and results This prespecified analysis from ODYSSEY OUTCOMES compared the effect of alirocumab vs. placebo in 18 924 patients with recent acute coronary syndrome (ACS) according to age. We examined the effect of assigned treatment on occurrence of the primary study outcome, a composite of coronary heart disease death, myocardial infarction, ischaemic stroke, or unstable angina requiring hospitalization [major adverse cardiovascular event (MACE)] and all-cause death. Relative risk reductions were consistent for patients >= 65 vs. = 75 vs. 0.85, 0.78-0.93 in
DOI:10.1093/eurheartj/ehz809